CLINICAL ROLE -
Future Treatment Landscape of MZL
Closing out their discussion on marginal zone lymphoma, the panel considers which future treatment strategies are most promising.
Other Approved Agents and Treatment Strategies for MZL
Moving beyond BTK inhibition in marginal zone lymphoma, expert panelists review other therapies and drug classes with indications in this setting.
Adverse-Event Management With BTK Inhibitors in MZL
Panelists look at the class effects of BTK inhibitors and share optimal strategies to select therapy and manage toxicities.
Zanubrutinib in Marginal Zone Lymphoma: The MAGNOLIA Trial
Expert perspectives on the MAGNOLIA trial and novel BTK inhibitor zanubrutinib in the context of marginal zone lymphoma treatment.
Improving Outcomes in Marginal Zone Lymphoma With BTK Inhibition
A broad review of BTK inhibition as a novel therapeutic approach toward the treatment of marginal zone lymphoma.
Understanding Second-Line Treatment Options for MZL
Following discussion on the NCCN guidelines for second-line therapy in marginal zone lymphoma, experts highlight approved treatment options.
Management of Patients With Marginal Zone Lymphoma: Current Treatment Options
Shared insight on treating marginal zone lymphoma with the current treatment armamentarium.
The Nature and Prevalence of Marginal Zone Lymphoma
Expert panelists review the pathophysiology of marginal zone lymphoma and reflect on its prevalence as a rare disease.
2 Commerce Drive Cranbury, NJ 08512